Funded Startups in Gosselies
Disclosed round sizes in Gosselies are concentrated at the top: Univercells raised $43M on 2022-10-19, which dwarfs the next-largest disclosed round, Endo…
Disclosed round sizes in Gosselies are concentrated at the top: Univercells raised $43M on 2022-10-19, which dwarfs the next-largest disclosed round, Endo Tools Therapeutics’ $23M on 2026-07-16. Below that, OncoDNA’s $19M (2020-02-14) forms a second tier, while Bone Therapeutics’ $4M (2021-12-03) and cikisi’s $3M (2023-09-01) sit near the floor of disclosed amounts.
The five most recent entries span 2020-02-14 through 2026-07-16, with only two closings after 2023-09-01 (cikisi’s $3M) and none between 2023-09-01 and 2026-07-16 aside from the newest entry. Sector-wise, biotechnology appears in three of five companies (Univercells, Bone Therapeutics, OncoDNA), while Information Technology and Health Care each account for one. Stage labels are sparse: two rows omit a stage value, including Endo Tools Therapeutics ($23M on 2026-07-16) and OncoDNA (2020-02-14).
Most recent rounds
5 shownRelated listings
Frequently asked
What does the size distribution look like for disclosed rounds in Gosselies?
Univercells’ $43M (2022-10-19) is the clear largest disclosed amount, landing well above the next-largest $23M from Endo Tools Therapeutics (2026-07-16). The remaining disclosed rounds cluster much closer together at $19M (OncoDNA, 2020-02-14), $4M (Bone Therapeutics, 2021-12-03), and $3M (cikisi, 2023-09-01).
Is there an over-represented sector among the five most recent funded companies?
Biotechnology accounts for 3 of 5 companies (Univercells, Bone Therapeutics, OncoDNA), while Health Care/Medical and Information Technology each appear once (Endo Tools Therapeutics; cikisi).
How concentrated are the deals in time, especially toward the most recent period?
The date range runs from 2020-02-14 (OncoDNA) to 2026-07-16 (Endo Tools Therapeutics). Only two entries occur after 2021-12-03: Bone Therapeutics’ $4M on 2021-12-03 is followed by 2022-10-19 (Univercells, $43M), then 2023-09-01 (cikisi, $3M), and finally 2026-07-16 (Endo Tools Therapeutics, $23M).
Which stage classifications show up most often, and are there missing stage labels?
Two of the five rows have a missing stage label (Endo Tools Therapeutics, $23M on 2026-07-16; OncoDNA, $19M on 2020-02-14). The other singletons are Seed (cikisi, $3M on 2023-09-01), Series D (Univercells, $43M on 2022-10-19), and Post-IPO Equity (Bone Therapeutics, $4M on 2021-12-03).
Are there outliers in disclosed funding size worth prioritizing?
Yes: the $43M Univercells round on 2022-10-19 stands far above the $23M Endo Tools Therapeutics (2026-07-16). The other disclosed amounts ($19M, $4M, $3M) are comparatively close to one another and notably below the top two levels (OncoDNA, Bone Therapeutics, and cikisi).
Know which startups just got funded. Every week.
Fresh funding rounds, new companies, and the sectors moving fastest — in your inbox every Monday morning.
Free. Sent every Monday. Unsubscribe anytime.